PL1680112T3 - N-(5-adamantan-1-ylometoksypentylo)deoksynojirimycyna lub dopuszczalna farmaceutycznie sól stosowane w leczeniu oporności na insulinę - Google Patents

N-(5-adamantan-1-ylometoksypentylo)deoksynojirimycyna lub dopuszczalna farmaceutycznie sól stosowane w leczeniu oporności na insulinę

Info

Publication number: PL1680112T3
Authority: PL; Poland
Prior art keywords: treatment; insulin resistance; deoxynojirimycin; adamantane; pentyl
Prior art date: 2003-10-29

Application number

PL04793684T

Other languages

English (en)

Inventor

Johannes Maria Franciscus Gerardus Aerts

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-29

Filing date

2004-10-29

Publication date

2011-05-31

2004-10-29 Application filed by Genzyme Corp filed Critical Genzyme Corp

2011-05-31 Publication of PL1680112T3 publication Critical patent/PL1680112T3/pl

Links

206010022489 Insulin Resistance Diseases 0.000 title abstract 2
LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 title abstract 2
150000003839 salts Chemical class 0.000 title abstract 2
208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 2
LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 title 1
208000031888 Mycoses Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
206010033307 Overweight Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
208000000069 hyperpigmentation Diseases 0.000 abstract 1
230000003810 hyperpigmentation Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Hematology (AREA)
Oncology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL04793684T 2003-10-29 2004-10-29 N-(5-adamantan-1-ylometoksypentylo)deoksynojirimycyna lub dopuszczalna farmaceutycznie sól stosowane w leczeniu oporności na insulinę PL1680112T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP03078396		2003-10-29
EP04076936		2004-07-06
PCT/NL2004/000760 WO2005039578A2 (en)	2003-10-29	2004-10-29	Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
EP04793684A EP1680112B1 (en)	2003-10-29	2004-10-29	N-(5-adamantane-1-yl-methoxy-pentyl)deoxynojirimycin or a pharmaceutically salt thereof for use in the treatment of insulin resistance

Publications (1)

Publication Number	Publication Date
PL1680112T3 true PL1680112T3 (pl)	2011-05-31

Family

ID=34524734

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04793684T PL1680112T3 (pl)	2003-10-29	2004-10-29	N-(5-adamantan-1-ylometoksypentylo)deoksynojirimycyna lub dopuszczalna farmaceutycznie sól stosowane w leczeniu oporności na insulinę

Country Status (11)

Country	Link
US (1)	US7662838B2 (pl)
EP (1)	EP1680112B1 (pl)
JP (1)	JP2007509925A (pl)
AT (1)	ATE491451T1 (pl)
AU (1)	AU2004283631A1 (pl)
CA (1)	CA2544086A1 (pl)
DE (1)	DE602004030604D1 (pl)
IL (1)	IL175259A0 (pl)
PL (1)	PL1680112T3 (pl)
PT (1)	PT1680112E (pl)
WO (1)	WO2005039578A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1528056A1 (en) *	2003-10-29	2005-05-04	Academisch Ziekenhuis bij de Universiteit van Amsterdam	Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
WO2005092334A2 (en) *	2004-03-25	2005-10-06	David Priestman	Use of n-substituted imino sugars for appetite suppression
EP1811991B1 (en)	2004-11-10	2018-11-07	Genzyme Corporation	Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
FR2887549B1 (fr) *	2005-06-23	2009-07-10	Centre Nat Rech Scient	Nouveaux composes de la famille des iminosucres, leurs utilisations, notamment pour le traitement de maladies lysosomales, ainsi que leur procede de preparation
SI2032134T1 (sl)	2006-05-09	2015-10-30	Genzyme Corporation	Postopki zdravljenja bolezni zamaščenih jeter, ki obsegajo inhibicijo sintezo glukosfingolipida
GB0614098D0 (en) *	2006-07-15	2006-08-23	Mnl Pharma Ltd	Immune response variegation with imino sugars
JP2008104399A (ja) *	2006-10-25	2008-05-08	Spirulina Biological Lab Ltd	糖尿病予防食品
EP2594564B1 (en)	2007-05-31	2016-09-28	Genzyme Corporation	2-acylaminopropanol-type glucosylceramide synthase inhibitors
CN101888840A (zh)	2007-10-05	2010-11-17	简詹姆公司	使用脑酰胺衍生物治疗多囊性肾疾病的方法
CA2731685A1 (en)	2008-07-28	2010-02-04	Genzyme Corporation	Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP3078373A1 (en)	2008-10-03	2016-10-12	Genzyme Corporation	2-acylaminopropanol-type glucosylceramide synthase inhibitor
EP2411526A4 (en) *	2009-03-27	2012-09-19	Zacharon Pharmaceuticals Inc	MODULATORS OF GANGLIOSID BIOSYNTHESIS
EP2731457A2 (en) *	2011-07-13	2014-05-21	Unilever PLC	Edible composition
JP2016513729A (ja) *	2013-03-15	2016-05-16	ユニザーヴィロロジー，エルエルシー	抗菌化合物
WO2022227287A1 (zh) *	2021-04-25	2022-11-03	中南大学	Dnj及其衍生物在制备预防和/或治疗肺动脉高压药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2504000B2 (ja)	1986-09-02	1996-06-05	日本新薬株式会社	グルコシルモラノリン誘導体
ATE322900T1 (de) *	1996-07-15	2006-04-15	Macrozyme Dnm B V	Deoxynojirimycin derivate und ihre verwendung als glukosesylceramidase-inhibitoren
BR9902585A (pt) *	1999-02-11	2000-09-26	Claudio Cerqueira Lopes	Um novo processo de sìntese de aza-açúcares com atividade biológica
GB0100889D0 (en)	2001-01-12	2001-02-21	Oxford Glycosciences Uk Ltd	Compounds
US6235737B1 (en)	2000-01-25	2001-05-22	Peter Styczynski	Reduction of hair growth
US20040204379A1 (en)	2000-06-19	2004-10-14	Cheng Seng H.	Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
MXPA04003536A (es) *	2001-10-15	2004-07-23	Genentech Inc	Tratamiento y diagnostico de estados resistentes a insulina.
EP1528056A1 (en) *	2003-10-29	2005-05-04	Academisch Ziekenhuis bij de Universiteit van Amsterdam	Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
WO2005063706A1 (en)	2003-12-23	2005-07-14	Macrozyme Dnm B.V.	Synthesis of nojirimycins
EP3782655A1 (en)	2005-05-17	2021-02-24	Amicus Therapeutics, Inc.	A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives

2004
- 2004-10-29 WO PCT/NL2004/000760 patent/WO2005039578A2/en not_active Ceased
- 2004-10-29 EP EP04793684A patent/EP1680112B1/en not_active Expired - Lifetime
- 2004-10-29 PL PL04793684T patent/PL1680112T3/pl unknown
- 2004-10-29 AU AU2004283631A patent/AU2004283631A1/en not_active Abandoned
- 2004-10-29 CA CA002544086A patent/CA2544086A1/en not_active Abandoned
- 2004-10-29 DE DE602004030604T patent/DE602004030604D1/de not_active Expired - Lifetime
- 2004-10-29 US US10/595,584 patent/US7662838B2/en not_active Expired - Lifetime
- 2004-10-29 AT AT04793684T patent/ATE491451T1/de not_active IP Right Cessation
- 2004-10-29 JP JP2006537908A patent/JP2007509925A/ja active Pending
- 2004-10-29 PT PT04793684T patent/PT1680112E/pt unknown
2006
- 2006-04-27 IL IL175259A patent/IL175259A0/en unknown

Also Published As

Publication number	Publication date
EP1680112B1 (en)	2010-12-15
US20070135487A1 (en)	2007-06-14
CA2544086A1 (en)	2005-05-06
WO2005039578A3 (en)	2005-09-29
AU2004283631A1 (en)	2005-05-06
IL175259A0 (en)	2006-09-05
PT1680112E (pt)	2011-03-24
EP1680112A2 (en)	2006-07-19
JP2007509925A (ja)	2007-04-19
US7662838B2 (en)	2010-02-16
DE602004030604D1 (de)	2011-01-27
WO2005039578A2 (en)	2005-05-06
ATE491451T1 (de)	2011-01-15

Publication	Publication Date	Title
PL1680112T3 (pl)	2011-05-31	N-(5-adamantan-1-ylometoksypentylo)deoksynojirimycyna lub dopuszczalna farmaceutycznie sól stosowane w leczeniu oporności na insulinę
TW200635582A (en)	2006-10-16	Medicaments for the treatment or prevention of fibrotic diseases
FI3457135T3 (fi)	2025-03-08	Fabryn taudin hoitovaihtoehtoja
WO2004030611A3 (en)	2004-06-17	Non-nucleoside reverse transcriptase inhibitors
TWI255817B (en)	2006-06-01	Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
TW200505881A (en)	2005-02-16	Tri(cyclo) substituted amide compounds
IL171683A (en)	2014-07-31	Immunosuppressive Compounds, Medicinal Products Containing Them and Their Use in the Preparation of Medication for Treatment
CY1112184T1 (el)	2015-12-09	Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
EP2371853A3 (en)	2012-10-03	Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment
SG150531A1 (en)	2009-03-30	Use of meloxicam for the treatment of respiratory diseases in pigs
UA92000C2 (en)	2010-09-27	1-benzylindole-2-carboxamide derivatives
MX2011013902A (es)	2012-02-23	Tratamiento de esclerosis multiple con laquinimod.
IL162765A (en)	2012-04-30	Diazabicycle derivatives, processes for their preparation, pharmaceutical compositions comprising them and their medical use
RU2004135563A (ru)	2005-06-10	Лекарственное средство для лечения повышенной активности мочевого пузыря
WO2006017188A3 (en)	2006-06-29	Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
JP2009500045A5 (pl)	2009-07-23
WO2007030944A3 (en)	2007-05-03	Methods of cardioprotection using dichloroacetate in combination with an inotrope
RU2007119067A (ru)	2008-11-27	Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
TW200637544A (en)	2006-11-01	Medicaments for the treatment or prevention of fibrotic diseases
WO2005082413A3 (en)	2006-08-24	Ciclesonide and glycopyrronium combination
RU2004105675A (ru)	2005-08-10	Способ комплексного лечения язв роговицы
JP2003119145A5 (pl)	2005-06-30
UA90843C2 (ru)	2010-06-10	Соединения три(цикло)-замещенных амидов
WO2007074170A3 (en)	2007-08-23	Compositions and methods for the treatment and prevention of disease
EE200400069A (et)	2004-08-16	Tsitalopraami kasutamine ravimkoostiste valmistamiseks kõrgenenud vererõhu raviks